Global Tardive Dyskinesia (TD) Treatment Drugs Market Size By Type (Valbenazine, Deutetrabenazine), By Application (Hospitals, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Tardive Dyskinesia (TD) Treatment Drugs Market was valued at USD 3.4 billion in 2023 and is expected to reach USD 6.7 billion by 2031, growing at a CAGR of 8.7% during the forecast period from 2023 to 2031. The rising global prevalence of neuropsychiatric disorders, particularly among aging populations and long-term antipsychotic users, is a key growth driver for this market. Tardive dyskinesia is a debilitating condition characterized by repetitive, involuntary movements, primarily affecting individuals on prolonged dopamine receptor-blocking therapies. The market is driven by the increasing awareness and diagnosis of TD, ongoing drug innovations, and supportive regulatory pathways for orphan and neurological disease treatments.

Drivers

Growing Prevalence of TD in Psychiatric Patients:

The increasing number of individuals diagnosed with schizophrenia, bipolar disorder, and major depression who are on long-term antipsychotic medications contributes significantly to the demand for TD treatment drugs.

Advancements in Neurotherapeutics:

Innovation in neuroscience has led to the development of VMAT2 inhibitors—such as valbenazine and deutetrabenazine—that specifically target TD symptoms, offering improved safety and efficacy.

Increased Awareness and Diagnosis:

Global awareness campaigns by healthcare organizations and pharmaceutical companies have significantly improved early detection and reporting of TD, facilitating timely treatment and better outcomes.

Restraints

High Cost of Branded VMAT2 Inhibitors:

Despite the clinical effectiveness, the cost of FDA-approved TD drugs remains high, limiting access in low-income regions and among uninsured populations.

Limited Number of Approved Therapies:

The current therapeutic landscape for TD includes only a few approved treatments, which could restrict competition and innovation in the absence of generics or biosimilars.

Opportunity

Expansion into Emerging Markets:

Untapped markets in Asia-Pacific, Latin America, and Africa present significant growth potential due to increasing investments in mental healthcare infrastructure and greater pharmaceutical outreach.

Pipeline Drug Approvals and R&D Investments:

Several pipeline candidates focusing on alternative mechanisms to treat TD are under clinical development, and their approval is expected to further boost the market.

Market by System Type Insights

Based on drug type, VMAT2 Inhibitors dominated the market in 2023, accounting for the largest revenue share due to their high efficacy and FDA approval status. Valbenazine and deutetrabenazine are currently the mainstays in TD treatment. The segment is expected to maintain dominance, but off-label drugs, such as benzodiazepines and anticholinergics, still hold relevance, especially in countries where approved treatments are less accessible.

Market by End-use Insights

The Hospital Pharmacy segment led the market in 2023, driven by the higher volume of prescriptions issued and administered in controlled clinical environments. However, Retail Pharmacies are expected to witness robust growth due to the increasing shift towards outpatient treatment and improved insurance coverage for chronic neurological disorders.

Market by Regional Insights

North America held the largest share of the global TD treatment drugs market in 2023, supported by strong healthcare infrastructure, high TD awareness, and favorable reimbursement policies. Europe followed closely, while the Asia-Pacific region is anticipated to register the fastest growth during the forecast period, attributed to increased mental health investments and growing geriatric populations in countries like Japan, China, and South Korea.

Competitive Scenario

Key players in the Global Tardive Dyskinesia Treatment Drugs Market include:

Neurocrine Biosciences Inc.

Teva Pharmaceutical Industries Ltd.

Lundbeck A/S

Amneal Pharmaceuticals Inc.

Sun Pharmaceutical Industries Ltd.

Dr. Reddy’s Laboratories

Mylan N.V.

Pfizer Inc.

These companies are engaging in strategic licensing agreements, investing in drug development, and seeking label expansions for existing TD drugs. For example:

In 2024, Neurocrine Biosciences expanded the use of valbenazine to adolescent populations under FDA priority review.

Teva Pharmaceuticals reported positive results from a Phase III trial evaluating deutetrabenazine for early-stage TD patients in 2023.

Scope of Work – Global Tardive Dyskinesia (TD) Treatment Drugs Market

Key Market Developments

2024: Neurocrine Biosciences initiated trials for a new VMAT2 inhibitor targeting treatment-resistant TD.

2023: Teva launched a digital adherence platform to support deutetrabenazine patients in the U.S.

2022: Lundbeck partnered with a leading neuroscience research institute to co-develop next-gen TD treatments.

FAQs

1) What is the current market size of the Global Tardive Dyskinesia (TD) Treatment Drugs Market?

The market was valued at USD 3.4 billion in 2023.

2) What is the major growth driver of the Global Tardive Dyskinesia (TD) Treatment Drugs Market?

The primary driver is the increasing prevalence of TD among long-term antipsychotic users and innovation in VMAT2 inhibitor therapies.

3) Which is the largest region during the forecast period in the Global Tardive Dyskinesia (TD) Treatment Drugs Market?

North America remains the largest region, driven by advanced healthcare systems and high awareness.

4) Which segment accounted for the largest market share in Global Tardive Dyskinesia (TD) Treatment Drugs Market?

The VMAT2 Inhibitors segment held the largest share in 2023.

5) Who are the key market players in the Global Tardive Dyskinesia (TD) Treatment Drugs Market?

Key players include Neurocrine Biosciences, Teva Pharmaceutical, Lundbeck A/S, Amneal Pharmaceuticals, and Sun Pharma.